Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: analysis of 8 clinical studies with selected patient groups on omega3-enriched medical nutrition.
Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: analysis of 8 clinical studies with selected patient groups on omega3-enriched medical nutrition.
Background & aims: The increased consumption of fish oil enriched-products exposes a wide diversity of people, including elderly and those with impaired health to relatively high amounts of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs). There is an ongoing debate around the possible adverse effects of n-3 LC-PUFAs on bleeding risk, particularly relevant in people with a medical history of cardiovascular events or using antithrombotic drugs.
Methods: This analysis of 8 clinical intervention studies conducted with enteral medical nutrition products containing fish oil as a source of n-3 LC-PUFAs addresses the occurrence of bleeding-related adverse events and effects on key coagulation parameters (Prothrombin Time [PT], (activated) and Partial Thromboplastin Time [(a)PTT]).
Results: In all the patients considered (over 600 subjects treated with the active product in total), with moderate to severe disease, with or without concomitant use of antithrombotic agents, at home or in an Intensive Care Unit (ICU), no evidence of increased risk of bleeding with use of n-3 LC-PUFAs was observed. Furthermore there were no statistically significant changes from baseline in measured coagulation parameters.
Conclusion: These findings further support the safe consumption of n-3 LC-PUFAs, even at short-term doses up to 10 g/day of eicosapentaenoic acid + docosahexaenoic acid (EPA + DHA) or consumed for up to 52 weeks above 1.5 g/day, in selected vulnerable and sensitive populations such as subjects with gastrointestinal cancer or patients in an ICU. We found no evidence to support any concern raised with regards to the application of n-3 LC-PUFAs and the potentially increased risk for the occurrence of adverse bleeding manifestations in these selected patient populations consuming fish oil enriched medical nutrition.
948-957
Jeansen, Stephanie
da789b72-bf54-48bd-8e23-036797cce836
Witkamp, Renger F.
32ae98fd-5d1d-45ea-9fa9-69d24ce94cbd
Garthoff, Jossie A.
67619208-9d4c-4b42-9b99-098dcac73b66
Helvoort, Ardy van
fd222844-fd3a-4da9-aecd-55f71ad22507
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
1 June 2018
Jeansen, Stephanie
da789b72-bf54-48bd-8e23-036797cce836
Witkamp, Renger F.
32ae98fd-5d1d-45ea-9fa9-69d24ce94cbd
Garthoff, Jossie A.
67619208-9d4c-4b42-9b99-098dcac73b66
Helvoort, Ardy van
fd222844-fd3a-4da9-aecd-55f71ad22507
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Jeansen, Stephanie, Witkamp, Renger F., Garthoff, Jossie A., Helvoort, Ardy van and Calder, Philip C.
(2018)
Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: analysis of 8 clinical studies with selected patient groups on omega3-enriched medical nutrition.
Clinical Nutrition, 37 (3), .
(doi:10.1016/j.clnu.2017.03.027).
Abstract
Background & aims: The increased consumption of fish oil enriched-products exposes a wide diversity of people, including elderly and those with impaired health to relatively high amounts of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs). There is an ongoing debate around the possible adverse effects of n-3 LC-PUFAs on bleeding risk, particularly relevant in people with a medical history of cardiovascular events or using antithrombotic drugs.
Methods: This analysis of 8 clinical intervention studies conducted with enteral medical nutrition products containing fish oil as a source of n-3 LC-PUFAs addresses the occurrence of bleeding-related adverse events and effects on key coagulation parameters (Prothrombin Time [PT], (activated) and Partial Thromboplastin Time [(a)PTT]).
Results: In all the patients considered (over 600 subjects treated with the active product in total), with moderate to severe disease, with or without concomitant use of antithrombotic agents, at home or in an Intensive Care Unit (ICU), no evidence of increased risk of bleeding with use of n-3 LC-PUFAs was observed. Furthermore there were no statistically significant changes from baseline in measured coagulation parameters.
Conclusion: These findings further support the safe consumption of n-3 LC-PUFAs, even at short-term doses up to 10 g/day of eicosapentaenoic acid + docosahexaenoic acid (EPA + DHA) or consumed for up to 52 weeks above 1.5 g/day, in selected vulnerable and sensitive populations such as subjects with gastrointestinal cancer or patients in an ICU. We found no evidence to support any concern raised with regards to the application of n-3 LC-PUFAs and the potentially increased risk for the occurrence of adverse bleeding manifestations in these selected patient populations consuming fish oil enriched medical nutrition.
Text
Article_Fatty acids and blood coagulation parameters_final-Revision 2
- Accepted Manuscript
Text
1-s2.0-S0261561417301188-main
- Version of Record
More information
Accepted/In Press date: 22 March 2017
e-pub ahead of print date: 29 March 2017
Published date: 1 June 2018
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 407788
URI: http://eprints.soton.ac.uk/id/eprint/407788
ISSN: 0261-5614
PURE UUID: 59194831-2f11-43e4-82f5-22662e55f99a
Catalogue record
Date deposited: 26 Apr 2017 01:07
Last modified: 16 Mar 2024 05:15
Export record
Altmetrics
Contributors
Author:
Stephanie Jeansen
Author:
Renger F. Witkamp
Author:
Jossie A. Garthoff
Author:
Ardy van Helvoort
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics